Aeglea’s search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%
Aeglea’s search for signs of efficacy in phase 3 rare [...]
Gilead’s CD47 trials freed of FDA hold—for the most part
Gilead’s CD47 trials freed of FDA hold—for the most part [...]
Liver enzyme might hold the secret to new obesity treatments
Liver enzyme might hold the secret to new obesity treatments [...]
AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target
AACR: Novartis hops on KRAS craze with early data, seeking [...]
AACR: C4’s multiple myeloma data prompts dosing switch, giving patients a longer treatment reprieve
AACR: C4’s multiple myeloma data prompts dosing switch, giving patients [...]
Cut the music: Kaleido calls it quits after FDA crackdown thwarted its pipeline plans
Cut the music: Kaleido calls it quits after FDA crackdown [...]
In just 72 words, BioCryst pauses enrollment for 3 mid-stage trials and sends shares tumbling
In just 72 words, BioCryst pauses enrollment for 3 mid-stage [...]
AACR: Blueprint wants to make resistance to AstraZeneca’s Tagrisso futile in lung cancer
AACR: Blueprint wants to make resistance to AstraZeneca’s Tagrisso futile [...]
Genfit bounces back from omicron to keep phase 3 trial on track
Genfit bounces back from omicron to keep phase 3 trial [...]
Final Aduhelm coverage decision keeps the door cracked open for Alzheimer’s therapies to come
Final Aduhelm coverage decision keeps the door cracked open for [...]